CLINICAL STUDIES ON PATIENTS WITH KNOWN OR SUSPECTED PARASITIC DISEASES

这些研究的目的是增加对发病机制的了解。 并改进其诊断、治疗和治疗 预防。除了在NIH的研究外，临床研究还包括 在危地马拉的流行区进行了患者检查。 (盘尾丝虫病)、印度和巴西(丝虫病)、贝宁(血吸虫病)、扎伊尔和 牙买加(铁线虫病)、洪都拉斯(利什曼病)和巴拿马 (利什曼病)。 实验室研究允许定义监管和 IgE、IgG4和嗜酸性粒细胞反应的致病机制 对蠕虫的感染，以及分子的鉴定 对贾第鞭毛虫病的抗原变异负责，并可能参与 班氏丝虫病、丝虫病和丝虫病的保护性免疫 棘球线虫病。 一种检测新的和专利前的盘尾丝虫病感染的诊断测试已经完成 用纯化的重组16kD蛋白(OV-16)开发。 伊维菌素治疗班氏丝虫病的临床对照试验 结果表明，它几乎和旧的抗丝虫病药物一样有效。 乙基卡马津，在清除微丝虫病方面同样安全；因为 它的单剂量口服治疗模式，应该要多得多 在控制程序中使用的实用性比乙基卡马津更好。

The goal of these studies is to increase understanding of the pathogenesis of parasitic diseases and to improve their diagnosis, therapy and prevention. In addition to studies at NIH, clinical investigation of patients has been carried out in the endemic areas of Guatemala (onchocerciasis), India and Brazil (filariasis), Benin (loiasis), Zaire and Jamaica (strongyloidiasis), Honduras (leishmaniasis) and Panama (leishmaniasis). Laboratory studies have permitted definition of the regulatory and pathogenetic mechanisms underlying the IgE, IgG4, and eosinophil responses to helminth infection, as well as the identification of molecules responsible for antigenic variation in giardiasis and likely involved in protective immunity in bancroftian filariasis, onchocerciasis and strongyloidiasis. A diagnostic test to detect new and prepatent onchocerciasis infections has been developed using a purified recombinant 16 kD protein (OV-16). Controlled clinical trials of ivermectin for bancroftian filariasis have shown it to be almost as effective as the older antifilarial drug diethylcarbamazine, and equally safe in clearing microfilaremia; because of its single-oral-dose mode of therapy, it should be considerably more practical for use in control programs than diethylcarbamazine has been.